Ocular Motor and Sensory Function in Parkinson's Disease

Published:September 29, 2011DOI:https://doi.org/10.1016/j.ophtha.2011.06.040

      Purpose

      To evaluate the effect of dopaminergic medication and deep brain stimulation on ocular function in Parkinson's disease (PD) and to measure vision-related quality of life in subjects with PD.

      Design

      Prospective, comparative case series.

      Participants and Controls

      Twenty-seven PD and 16 control subjects were recruited.

      Methods

      Visual acuity, ocular motor function, convergence, and vision-related quality of life using the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) were measured. Visual sensory and motor measurements were obtained during the on and off states of PD dopaminergic treatment.

      Main Outcome Measures

      Convergence ability and vision-related quality of life.

      Results

      The PD subjects had a mean age of 58.8 years; 30% were female. Their mean duration of PD was 10.9±6.8 years. The control subjects had a mean age of 61.6 years; 56% were female. There was no difference in visual acuity, contrast sensitivity, or color vision of the PD subjects in their on state compared with controls. Convergence amplitudes measured with base-out prism were significantly poorer in PD subjects in their on state compared with controls (24.1±8 Δ vs. 14.8 ±10.3 Δ; P = 0.003). The mean composite VFQ-25 score was significantly worse in the PD subjects compared with the controls (87.1±8.69 vs. 96.6±3.05; P = 0.0001). Comparing the PD subjects in their on with their off states, there was no difference in distance exodeviation, near exodeviation, or ocular ductions. Mean convergence amplitudes and near point of convergence were better in the on state compared with the off state: 14.8±10.3 Δ versus 10.7±9.0 Δ ( P = 0.0006) and 13.1±9.1 cm versus 18.1±12.2 cm ( P = 0.002), respectively.

      Conclusions

      Convergence ability is significantly poorer in PD subjects in both the on and off states compared with controls, but improves significantly with systemic dopaminergic treatment. Ocular motor function in PD subjects fluctuates in response to treatment, which complicates ophthalmic management. Parkinson's disease subjects have a significant reduction in vision-related quality of life, especially with near activities, that is not associated with visual acuity.

      Financial Disclosure(s)

      The author(s) have no proprietary or commercial interest in any materials discussed in this article.

      References

        • Harris M.K.
        • Shneyder N.
        • Borazanci A.
        • et al.
        Movement disorders.
        Med Clin North Am. 2009; 93 (viii): 371-388
        • Hunt L.A.
        • Sadun A.A.
        • Bassi C.J.
        Review of the visual system in Parkinson's disease.
        Optom Vis Sci. 1994; 72: 92-99
        • Biousse V.
        • Skibell B.C.
        • Watts D.N.
        • et al.
        Ophthalmologic features of Parkinson's disease.
        Neurology. 2004; 62: 177-180
        • Repka M.X.
        • Claro M.C.
        • Loupe D.N.
        • Reich S.G.
        Ocular motility in Parkinson's disease.
        J Pediatr Ophthalmol Strabismus. 1996; 33: 144-147
        • Uc E.Y.
        • Rizzo M.
        • Anderson S.W.
        • et al.
        Visual dysfunction in Parkinson disease without dementia.
        Neurology. 2005; 65: 1907-1913
        • Racette B.A.
        • Gokden M.S.
        • Tychsen L.S.
        • Perlmutter J.S.
        Convergence insufficiency in idiopathic Parkinson's disease responsive to levodopa.
        Strabismus. 1999; 7: 169-174
        • Deuschl G.
        • Schade-Brittinger C.
        • Krack P.
        • et al.
        • German Parkinson Study Group, Neurostimulation Section
        A randomized trial of deep-brain stimulation for Parkinson's disease.
        N Engl J Med. 2006; 355: 896-908
        • Limousin P.
        • Krack P.
        • Pollak P.
        • et al.
        Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease.
        N Engl J Med. 1998; 339: 1105-1111
        • Priori A.
        • Cinnante C.
        • Genitrini S.
        • et al.
        Non-motor effects of deep brain stimulation of the subthalamic nucleus in Parkinson's disease: preliminary physiological results.
        Neurol Sci. 2001; 22: 85-86
        • Mangione C.M.
        • Lee P.P.
        • Gutierrez P.R.
        • et al.
        • National Eye Institute Visual Function Questionnaire Field Test Investigators
        Development of the 25-item National Eye Institute Visual Function Questionnaire.
        Arch Ophthalmol. 2001; 119: 1050-1058
        • Hoehn M.M.
        • Yahr M.D.
        Parkinsonism: onset, progression and mortality.
        Neurology. 1967; 17: 427-442
        • Goetz C.G.
        • Tilley B.C.
        • Shaftman S.R.
        • et al.
        • Movement Disorder Society UPDRS Revision Task Force
        Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.
        Mov Disord. 2008; 23: 2129-2170
        • Beck R.W.
        • Moke P.S.
        • Turpin A.H.
        • et al.
        A computerized method of visual acuity testing: adaptation of the Early Treatment of Diabetic Retinopathy Study testing protocol.
        Am J Ophthalmol. 2003; 135: 194-205
        • Pelli D.G.
        • Robson J.G.
        • Wilkins A.J.
        The design of a new letter chart for measuring contrast sensitivity.
        Clin Vis Sci. 1988; 2: 187-199
        • Cheng E.M.
        • Tonn S.
        • Swain-Eng R.
        • et al.
        • American Academy of Neurology Parkinson Disease Measure Development Panel
        Quality improvement in neurology: AAN Parkinson disease quality measures.
        Neurology. 2010; 75: 2021-2027
        • Bühren J.
        • Terzi E.
        • Bach M.
        • et al.
        Measuring contrast sensitivity under different lighting conditions; comparison of three tests.
        Optom Vis Sci. 2006; 83: 290-298
        • Mantyjarvi M.
        • Laitinen T.
        Normal values for the Pelli-Robson contrast sensitivity test.
        J Cataract Refract Surgery. 2001; 27: 261-266